Assembly Biosciences Announces Pricing of $60 Million Offering of Common Stock
November 02, 2017 00:40 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) (“Assembly” or the “Company”), a clinical-stage biotechnology company advancing a new class of oral...
Assembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development
September 25, 2017 07:00 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
Assembly Biosciences Announces September Conference Participation
August 31, 2017 07:00 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
ContraVir Pharmaceuticals to Present at BIO-Europe Spring 2017
March 14, 2017 06:00 ET
|
ContraVir Pharmaceuticals Inc
EDISON, N.J., March 14, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral...
Assembly Biosciences to Present Data on ABI-H0731 at AASLD 2016 Liver Meeting
November 11, 2016 08:00 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
Assembly Biosciences Initiates Phase 1 Clinical Program of ABI-H0731 for Treatment of Chronic Hepatitis B Virus Infection
November 09, 2016 07:05 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
November 04, 2015 16:01 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 4, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
Assembly Biosciences to Describe Improved Methods for HBV Drug Development at Major International Meeting
October 06, 2015 07:00 ET
|
Assembly Biosciences, Inc.
—Data to Be Presented at 2015 International Meeting on the Molecular Biology of Hepatitis B Describes Improved Methods for Measuring Key Biomarkers for Curative Therapies— —Assembly Also...
TetraLogic Reports Second Quarter Financial Results and Provides Clinical Programs Update
August 05, 2015 16:01 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Aug. 5, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Provides Update on Hepatitis B Clinical Program
July 20, 2015 16:02 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., July 20, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) a clinical-stage biopharmaceutical company focuses on discovering and developing novel small...